Using AI to improve detection and prediction of cerebral aneurysms

Artificial Intelligence Applications for Cerebral Aneurysms Segmentation, Detection and Stability Prediction: a Stepwise, Multicenter Study

Observational Shanghai Jiao Tong University Affiliated Sixth People's Hospital · NCT06766422

This study is testing whether using artificial intelligence can help doctors find and predict the risk of unruptured brain aneurysms more accurately to better protect patients.

Quick facts

Study typeObservational
Enrollment10000 (estimated)
Ages18 Years and up
SexAll
SponsorShanghai Jiao Tong University Affiliated Sixth People's Hospital Academic / other
Locations1 site (Shanghai)
Trial IDNCT06766422 on ClinicalTrials.gov

What this trial studies

This observational study focuses on the application of artificial intelligence models to enhance the segmentation, detection, and stability prediction of unruptured cerebral aneurysms. By utilizing advanced imaging techniques like magnetic resonance angiography (MRA) and computed tomography angiography (CTA), the study aims to improve diagnostic accuracy and identify high-risk aneurysms that are more likely to rupture. This approach seeks to alleviate the workload of diagnostic physicians while ensuring timely intervention for patients at risk of aneurysmal subarachnoid hemorrhage.

Who should consider this trial

Good fit: Ideal candidates for this study are adults aged 18 and older who have been diagnosed or show symptoms of a cerebral aneurysm and are undergoing relevant imaging procedures.

Not a fit: Patients with other intracranial vascular diseases or those who have had previous intracranial interventions may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could lead to more accurate identification of high-risk cerebral aneurysms, potentially reducing the incidence of ruptures and improving patient outcomes.

How similar studies have performed: While the use of AI in medical imaging is a growing field, this specific application for cerebral aneurysms is relatively novel and has not been extensively tested in prior studies.

Eligibility criteria

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Age ≥ 18 years;
2. Preliminary diagnosis or symptoms indicating the presence or potential presence of a cerebral aneurysm;
3. Undergoing a non-contrast head MRA or contrast-enhanced head/neck CTA;
4. The patient or their legal representative is able and willing to sign an informed consent form.

Exclusion Criteria:

1. Other intracranial vascular diseases: moyamoya disease, arteriovenous malformations, arteriovenous fistulas, arterial occlusions, and arterial dissections;
2. History of intracranial arterial interventions: stent placement, partial aneurysm coil treatment, etc.;
3. Severe allergy to contrast agents or absolute contraindications to iodine-based contrast agents;
4. Renal insufficiency with elevated serum creatinine (greater than twice the upper normal limit);
5. MRI contraindications: pacemakers, claustrophobia, etc.;
6. Diseases or conditions that affect the quality of CTA/MRA images;
7. Inability to complete the study due to psychiatric disorders, cognitive, or emotional disturbances.

Note: The CTA sub-study does not include exclusion criterion 5; the MRA sub-study does not include exclusion criteria 3 and 4.

Where this trial is running

Shanghai

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions Unruptured Cerebral AneurysmArtificial IntelligenceSubarachnoid Hemorrhage, AneurysmalMagnetic Resonance AngiographyCerebral AneurysmsSubarachnoid Hemorrhage
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.